All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Maintenance With Niraparib and Ipilimumab Demonstrates PFS Benefit in Pancreatic Cancer

August 23rd 2022

Niraparib plus ipilimumab maintenance therapy elicited encouraging progression-free survival results in patients with advanced pancreatic cancer who achieved a stable response to platinum-based chemotherapy.

Tislelizumab/Chemo Combo Takes Step Toward Chinese Approval for Unresectable ESCC

August 23rd 2022

The China National Medical Products Administration’s Center for Drug Evaluation has accepted for review a supplemental biologics application seeking the approval of tislelizumab plus chemotherapy in the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas

August 23rd 2022

The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.

EMA Validates Marketing Authorization Application for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

August 23rd 2022

The European Medicines Agency has validated the marketing authorization application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.

Online Testing Tool Identifies People Likely to Benefit from Genetic Testing for Inherited Risk for Certain Cancers

August 23rd 2022

An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, a new study shows.

FDA Grants Breakthrough Therapy Designation to Taletrectinib for ROS1+ NSCLC

August 23rd 2022

The FDA has granted a breakthrough therapy designation to taletrectinib for use as a potential therapeutic option in adult patients with advanced or metastatic ROS1-positive non–small cell lung cancer who were ROS1 inhibitor naïve or who previously received crizotinib.

EMA Accepts Marketing Authorization Application for Fixed-Dose Decitabine/Cedazuridine Combo in AML

August 22nd 2022

The European Medicines Agency has accepted the marketing authorization application for the oral fixed-dose combination of decitabine and cedazuridine for the frontline treatment of adults with acute myeloid leukemia who are not candidates for standard induction chemotherapy.

Zolbetuximab Plus Gemcitabine and Nab-Paclitaxel Under Investigation in Claudin 18.2+ Metastatic Pancreatic Cancer

August 22nd 2022

Wungki Park, MD, discussed the rationale of targeting CLDN18.2 in patients with pancreatic cancer, preclinical data supporting the use of zolbetuximab in this patient population, and the key objectives of the ongoing phase 2 trial

Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL

August 22nd 2022

Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.

Perioperative Immunotherapy Demonstrates Promising pCR Rates in dMMR/MSI-H Gastric and GEJ Cancer

August 22nd 2022

Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited positive pathologic complete response rates in patients with locally advanced resectable mismatch repair–deficient and/or microsatellite instability–high gastric or gastroesophageal junction adenocarcinoma.

New Breast Center at UI Health Care Aims to Ease the Cancer Journey for Patients

August 22nd 2022

The new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.

EMA Accepts Marketing Authorization Application for Elacestrant in ER+/HER2- Advanced Breast Cancer

August 22nd 2022

The European Medicines Agency has validated a marketing authorization application for elacestrant for estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

Promising Data for Treatment of Myelofibrosis Emerges With Pelabresib and Ruxolitinib Combination

August 22nd 2022

John Mascarenhas, MD, discussed the effect of the data from MANIFEST on the treatment landscape and the future of adding active agents to ruxolitinib for treatment of myelofibrosis.

Analysis Reveals Racial Disparities in Timeliness of Treatment With IMRT Among Individuals With Cancer

August 22nd 2022

Non-Hispanic Black, Hispanic, and Asian patients with cancer are significantly more likely to experience delays in receiving intensity-modulated radiotherapy.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

August 20th 2022

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

Bevacizumab Biosimilar CT-P16 Approved in Europe for Multiple Cancer Types

August 19th 2022

The European Commission has approved the bevacizumab biosimilar, CT-P16, for the treatment of patients with metastatic breast cancer, non–small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer, and cervical cancer.

Rucaparib Maintenance Extends PFS in DRD+ Metastatic Urothelial Cancer

August 19th 2022

Maintenance therapy with rucaparib following platinum-based chemotherapy prolonged progression-free survival compared with placebo in patients with DNA repair–deficient-positive, metastatic urothelial cancer.

Trastuzumab Deruxtecan Expands the Targeted Landscape for HER2-mutant NSCLC

August 19th 2022

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

Concurrent Galunisertib and Neoadjuvant Chemoradiotherapy Improves CR Rates in Rectal Cancer

August 19th 2022

The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.

FDA Grants Orphan Drug Designation to Fixed-Dose Senaparib/Temozolomide Combo for SCLC

August 19th 2022

The FDA has granted an orphan drug designation to the fixed-dose combination capsule of the PARP inhibitor senaparib and temozolomide for the treatment of adult patients with small cell lung cancer.